Cost of Revenue Trends: GSK plc vs Exelixis, Inc.

Cost of Revenue: A Tale of Two Companies

GSK plc vs Exelixis, Inc.

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. From 2014 to 2023, GSK plc and Exelixis, Inc. have shown contrasting trends in their cost of revenue. GSK, a global healthcare giant, consistently reported costs in the billions, peaking in 2019 with a 62% higher cost than in 2014. Meanwhile, Exelixis, a biotechnology firm, saw a dramatic increase, with costs rising over 3,400% from 2014 to 2023. This surge reflects Exelixis's aggressive growth strategy and increased production to meet rising demand. By 2023, Exelixis's cost of revenue was approximately 0.85% of GSK's, highlighting the scale difference between the two. These trends underscore the diverse strategies and market positions of these companies, offering insights into their operational efficiencies and market dynamics.